Iovance Biotherapeutics exceeded revenue expectations in its recent quarterly report, with a 8.8% revenue beat and a 6.0% smaller loss per share than expected.
Read MoreDid you find this insightful?
Bad
Just Okay
Amazing
Iovance Biotherapeutics, Inc. (NASDAQ:IOVA) Third-Quarter Results: Here's What Analysts Are Forecasting For Next Year
